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SATU KAJIAN BERSAMA PENYALAHGUNA KETAMINE DI 
GEORGETOWN, KUALA LUMPUR DAN JOHOR BAHRU 
 
ABSTRAK 
Ketamine N-methyl-D-aspartat (NMDA) merupakan agen anestetik, digunakan 
secara luas sebagai ‘club-drug’. Sehingga kini, tiada data mengenai demografi sosio 
pengguna ketamine di Malaysia. Kajian ini bertujuan untuk mengkaji demografi sosio 
dan masalah kesihatan berkaitan dengan penggunaan ketamine dalam kalangan 
pengguna ketamine. Sejumlah n=150 pengguna ketamine menyertai kajian keratan-
rentas ini. Responden telah direkrut melalui teknik persampelan purposif dan ‘snowball’ 
dari tiga negeri (Pulau Pinang, Kuala Lumpur dan Johor) di mana penggunaan ketamine 
dilaporkan berleluasa. Semua soal-selidik dilakukan secara temubual oleh seorang 
pembantu penyelidik yang terlatih. Responden telah dibahagikan kepada dua kumpulan 
berdasarkan tempoh penggunaan ketamine (<2 tahun sebagai jangka pendek dan ≥2 
tahun sebagai jangka panjang). Analisis kajian dibahagikan kepada dua bahagian iaitu; 
(i) jumlah sempel n=150 dan (ii) sampel lelaki n=127 (pengguna ketamine sahaja n=36 
dan pengguna ketamine ‘poly-drug’ n=91). Kebanyakan adalah lelaki, terutamanya etnik 
Cina.  Min umur responden dalam kajian ini ialah 28.7 tahun (SD=8.46). Sejumlah besar 
mengaku menggunakan ketamine bersama dadah lain (pengguna ketamine ‘poly-drug’) 
(n=107). Pengguna ketamine jangka panjang (n=150) mempunyai kemungkinan yang 
tinggi untuk mengalami masalah urologi seperti peningkatan kekerapan kencing (OR: 
2.89: 1.36-6.15: p<0.004), kerap kencing di waktu malam (OR: 2.23: 1.115-4.32: 
p<0.013), kesukaran mengawal kencing (OR: 3.10: 1.57-6.13: p<0.001), tiba-tiba rasa 
xvi 
 
hendak kencing (OR: 2.28: 1.12-4.65: p<0.017), sakit dibahagian bawah perut semasa 
kencing (OR: 4.47: 2.23-8.96: p<0.000) dan sakit semasa kencing (OR: 3.14: 1.57-6.27: 
p<0.001),  berbanding  dengan pengguna ketamine jangka pendek. Manakala, bagi 
responden lelaki n=127, responden yang mengunakan ketamine sahaja (n=36) untuk 
jangka panjang mempunyai kemungkinan yang tinggi untuk mengalami masalah urologi 
seperti kerap kencing di waktu malam (OR: 16: 2.7-93.6: p<0.001) dan tiba-tiba rasa 
hendak kencing (OR: 6: 1.1-33.3: p<0.030), berbanding dengan pengguna ketamine 
jangka pendek. Sebaliknya, pengguna ketamine ‘poly-drug’ (n=91) jangka panjang 
mempunyai kemungkinan yang tinggi untuk mengalami lebih banyak masalah urologi 
seperti peningkatan kekerapan kencing (OR: 3.7: 1.42-9.44: p<0.006), sukar mengawal 
kencing (OR: 6.2: 2.5-15.4: p<0.000), sakit dibahagian bawah perut semasa kencing 
(OR: 7.6: 2.9-19.53: p<0.000) dan sakit semasa kencing (OR: 4.6: 1.9-11.42: p<0.001), 
berbanding dengan pengguna ketamine ‘poly-drug’ jangka pendek. Terutama sekali, 
pengguna jangka panjang iaitu pengguna ketamine sahaja (OR: 6.1: 1.4-26.9: p<0.013) 
dan ketamine poly-drug (OR: 5.8: 2.3-14.45: p<0.000) mempunyai risiko yang tinggi 
untuk mengalami masalah mati pucuk, berbanding dengan pengguna jangka pendek. 
Masalah kesihatan berkaitan dengan penggunaan ketamine di Malaysia perlu diberi 
perhatian. Kajian ini menyokong kajian semasa bahawa penggunaan ketamine boleh 
menyebabkan masalah urologi. Ini merupakan kajian pertama yang telah mengenal pasti 
masalah mati pucuk di kalangan pengguna ketamine lelaki.  
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A STUDY ON KETAMINE ABUSERS IN GEORGETOWN, KUALA LUMPUR 
AND JOHOR BAHRU 
 
ABSTRACT 
Ketamine an N-methyl-D-aspartate (NMDA) is an anaesthetic agent, widely 
used as a club-drug. To date, there is no data on the socio-demographic characteristics of 
ketamine users in Malaysia. This study aims to investigate the socio-demographic 
characteristics and health problems associated with ketamine use among regular 
ketamine users. A total of n=150 ketamine users participated in this cross-sectional 
study. Respondents were recruited through purposive and snowball sampling from three 
states (Penang, Kuala Lumpur and Johor) where ketamine use was reported to be 
widespread. All the surveys were conducted through face-to-face interviews by one 
trained research assistants. Respondents were divided into two groups based on their 
duration of ketamine use (short-term <2 and long-term users ≥2 years). The study 
analysis is divided into two parts; (i) total sample n=150, and (ii) male sample n=127 
(those who reported ketamine use only n=36 and ketamine poly-drug use n=91). Most 
were males, predominantly of Chinese ethnicity. The respondents mean age in this study 
was 28.7 years-old (SD=8.46). A substantial number reported to use ketamine with other 
drugs (ketamine poly-drug use) (n=107). Long-term ketamine users n=150, have higher 
odds of experiencing urological problems such as frequent urination (OR: 2.89: 1.36-
6.15: p<0.004), nocturia (OR: 2.23: 1.115-4.32: p<0.013), incontinence (OR: 3.10: 1.57-
6.13: p<0.001), urgency (OR: 2.28: 1.12-4.65: p<0.017), interstitial cystitis (OR: 4.47: 
2.23-8.96: p<0.000) and dysuria (OR: 3.14: 1.57-6.27: p<0.001), compared to short-term 
xviii 
 
ketamine users. While for male respondents n=127, long-term ketamine users who 
reported ketamine use only were more likely to experience urological problems such as 
nocturia (OR: 16: 2.7-93.6: p<0.001) and urgency (OR: 6: 1.1-33.3: p<0.030) than short-
term ketamine users. Conversely, long-term ketamine poly-drug users had higher odds 
of reporting more urological problems such as frequent urination (OR: 3.7: 1.42-9.44: 
p<0.006), incontinence (OR: 6.2: 2.5-15.4: p<0.000), interstitial cystitis (OR: 7.6: 2.9-
19.53: p<0.000) and dysuria (OR: 4.6: 1.9-11.42: p<0.001) compared to short-term 
ketamine poly-drug users. Both long-term users who reported ketamine use only (OR: 
6.1: 1.4-26.9: p<0.013) and ketamine poly-drug use (OR: 5.8: 2.3-14.45: p<0.000) were 
more likely to report erectile-dysfunction than short-term users. There is a need to 
address the health problems associated with ketamine use in Malaysia. This study 
supports the current literature that ketamine use can cause urological problems. This is 
the first study to identify erectile-dysfunction problem in regular male ketamine users.  
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CHAPTER   1 
 
INTRODUCTION 
1.0 Introduction 
This chapter introduces the first topic of the thesis. The world drug problem and 
Malaysia drug abuse problems are discussed in this chapter. The scope of study, research 
questions, research objectives, and study limitations are also described in this chapter.  
1.1 World Drug Problem 
Based on the 2014 World Drug Report from United Nations Office on Drugs and 
Crime (UNODC) indicated a total of 243 million people (scope 162-324 million) 
corresponding to some 5.2% (scope 3.5-7.0%) of the world population aged between 15 
to 64 years had used an illicit drug, primarily cannabis, opioid, cocaine or 
Amphetamine-Type-Stimulant (ATS) at least once in the previous year (UNODC, 
2014). In contrast, men are two to three times more likely than women to have used an 
illicit substance. Overall, the global prevalence of illicit drug use and problem drug use 
(those with substance use disorders) remains stable, as shown in Figure 1.1. A marked 
increase is also reported in opioid and cannabis use since 2009, whereas the use of 
opiates, cocaine and ATS (excluding ecstasy) has remained stable.  
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       Figure 1.1 Global trends in drug use 2006 to 2012 
                                                                                        
      
                                                                                 Source: UNODC, 2014: pp.1. 
‘Poly-drug’ use (multidrug use) is another emerging problem that has recently 
received significant attention from treatment providers. The problem of multidrug use 
could undermine drug users’ recovery program. UNODC reported that the emergence of 
poly-drug use among illicit drug users mainly occurs where a different substance is 
being taken together 1) to obtain complementary effects, 2) to ease the adverse effects of 
another drug, and 3) when a drug is gradually replaced or being substituted with another 
drug due to changes in price and drug availability, otherwise the drug is used because of 
fashion (UNODC, 2014:pp.1). The abuse of ketamine may lead to serious health 
problems. Despite the growing abuse of non-medical ketamine use in various parts of 
the world (Ng et al., 2012; Huang et al., 2008; Chu et al., 2008; Shahani et al., 2007; 
Garcia-Larrosa et al., 2012; Pal et al., 2013; Winstock et al., 2012), ketamine is also 
reported to be used in Malaysia among ‘club goers’ in entertainment settings (Robson et 
al., 2010). There are still limited data on ketamine use among ketamine users in 
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Malaysia, and this warrants further investigation as a result of its deleterious side-effects 
on lower urinary tract (Pal et al., 2013; Shahani et al., 2007; Mak et al., 2011; Chen et 
al., 2011).  
In addition, UNODC estimated that approximately 1 in 6 problem drug users 
access treatment each year (UNODC, 2014). UNODC also estimated that there were 
around 183,000 drug-related deaths in 2012, corresponding to a mortality rate of 40% 
deaths per million persons aged 15 to 64 years. Drug overdose is the main contributor to 
the global number of drug-related deaths. In fact, opioids (heroin and non-medical use of 
prescription opioids) are the main type of drug that has led to accidental deaths among 
opiate users. Unsafe injecting practices could also pose significant health consequences. 
The United Nations Joint Programme on HIV/AIDS claimed that the number of new 
cases of HIV among injecting drug users are still high. UNODC estimated that there are 
about 12.7 million injecting drug users around the world (UNODC, 2014). While HIV 
prevalence among people who inject drugs is 22 times higher than the general 
population. It is estimated that there are around 6,190,000 injecting drug users in Asia 
(UNODC, 2014). About 1.7 million IDUs are reported to be infected with HIV in 2012, 
of this percentage 52% (850,000 people) are living with Hepatitis C. Hence, addressing 
HIV among people who inject drugs still remains a major challenge in most countries 
despite the implementation of various evidence-based harm reduction programs.  
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Apart from the health burden created by illicit drug use, production and 
trafficking of illicit drugs continues to escalate. Traditional drugs such as opiates/opioids 
are still widely used in most countries. UNODC reported that the opium cultivation area 
in Afghanistan has increased from 154,000 hectares in 2012 to 209,000 hectares in 2013 
(UNODC, 2014). While, the global area for illicit opium cultivation in 2013 stood at 
296,720 hectares, and the production of opium in 2013 is estimated to be at 6,883 tons, 
and heroin (of different purity) has increased to 560 tons (UNODC, 2014). Conversely, 
global seizure for heroin and illicit morphine fall to 19% in 2012. On the other hand, 
clandestine ATS manufacturing laboratories has increased from 12,571 labs in 2011 to 
14,322 labs in 2012 (UNODC, 2014). In fact, over the past five years, seizures for 
methamphetamine have almost quadrupled from 24 tons in 2008 to 114 tons in 2012. 
UNODC (2014) report also indicated a marked increased in the number of people 
seeking treatment for ketamine use in the United Kingdom over the last six years.     
1.2 Malaysia Drug Abuse Problem 
Malaysia is not spared from the global drug abuse problem. The history of 
substance abuse in Malaysia is largely influenced by the pre and post independent 
period. Before independence, opium was largely consumed by immigrants from China 
and India who were brought by the British to work in tin mines and rubber plantations in 
Malaya. In fact, migrant workers commonly used opium as a remedy to treat common 
medical problems, as well as to enhance work performance to laborious work (Adilah, 
1985). In fact, after independence era many young adults were strongly influenced by 
the ‘hippy’ subculture. This hippy culture was introduced by the American soldiers 
(deployed to fight the Vietnam War) who usually visited Malaysia to spend their 
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holidays. Since then morphine popularity begin to attract wider appeal particularly in 
adolescents. Most of the opium smoking ports in Malaya were slowly criminalized by 
the British under the Dangerous Drug Ordinance 1952. This restriction was mainly 
imposed to control the growing abuse and illegal distribution of opium among the 
Chinese triads in Malaya (Adilah, 1985). Hence, during the same period of time 
marijuana consumption became popular among the Malays compare to other ethnic 
groups (Navaratnam, 1988). In fact, the substance abuse problem escalated vastly in the 
70’s and 80’s in Malaya. However, since 1996 other challenging issues surfaced with the 
increasing transmission of HIV among opiate IDUs who engaged in risky injecting and 
needle sharing behaviours (Chawarski et al., 2006). Receptive injecting and sexual risk 
behaviours have been acknowledged to be the primary risk factors for HIV transmission 
among opiate users in Malaysia (Vicknasingam et al., 2009).  
      The two main sources of data on the number of drug users in the country are 
documented by the National Anti-drugs Agency (NADA) and the Royal Malaysia Police 
(RMP). Figures from National Drug Report 2014, showed fluctuating trends in the 
number of people detected for illicit drug use from year 2004 to 2014, Figure 1.2. While 
there has been a decrease from year 2004 (38,672) to 2007 (14,489), a slight increase is 
observed from year 2008 (12,352) to 2010 (23,642) again followed by a decrease from 
2010 (23,642) to 2012 (15,101) and an increase from year 2013 (20,887) to 2014 
(21,777). These fluctuating trends do not really describe the situation of drug use in the 
country. On the other hand, RMP data related to drug use arrests is also shown in Figure 
1.3. Similarly, a fluctuating trend is observed for opiate and cannabis users arrests where 
there was a decrease from year 2006 (45,451) to 2008 (41,363). An increase is observed 
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between years 2008 (41, 363) and 2010 (63,466). This is followed by a decrease since 
year 2010 (63,466) to 2014 (39,940).        
 Figure 1.2 Number of drug addicts detected from year 2004 to2014. 
 
   
                                                                         Source: National Drug Report, 2014.  
    
Figure 1.3 Total arrest under section 3(1) Drug Dependents Act (Treatment and 
Rehabilitation) 1983 related to opiate and cannabis drug use from 2006 to 2014. 
 
                                                                                                    
 
                                                                           Source: Royal Malaysia Police, 2014.  
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        While the number of opiate and cannabis users showed a fluctuating trend in the 
country, the latest figures from RMP (2014) showed the number of people arrested for 
ATS use has increased exponentially from 21,654 in 2006 to 81,435 in 2014, as shown 
in Figure 1.4.  
 
Figure 1.4 Total arrest under section 15 (1) (a) Dangerous Drugs Act 1952 for party 
drugs from 2006 to 2014. 
 
 
                   
                                                                          Source: Royal Malaysia Police, 2014. 
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In an attempt to get a better understanding on the substance abuse situation in the 
country, drug seizure data is also reviewed. Figures from RMP (2014), showed seizure 
for methamphetamine have increased from 609kg in 2012 to 1246kg in 2013, and 
decreased in 2014 to 762kg as shown in Figure 1.5. Heroin seizure also increased from 
445kg in 2011 to 639kg in 2013, and decreased in 2014 to 381kg. During this same 
period, a decreasing trend was observed for the arrests of opiate users as shown in 
Figure 1.3. Ketamine seizures show a decreasing trend from year 2009 (378kg) to 2011 
(106kg) followed by an increasing trend from 2012 (118kg) to 2014 (217kg).    
   
      Figure 1.5 Drug Seizures from 2009 to 2014 
 
       
 
                                                                           Source: Royal Malaysia Police, 2014.                                                 
 
Other sources of data show a higher estimate of drug users in the country, The 
Malaysian Psychiatric Association (2006) estimates that there are about 1 million people 
who use illicit drugs in Malaysia. It is also estimated that there is about 170,000 IDUs in 
Malaysia, and the HIV prevalence in IDU population is estimated to be around 15.9%-
19.0% (Ministry of Health Malaysia, 2010).  
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The varying trends in opiate users detected and arrested may be due to various 
factors. One of the main reasons could be due to the implementation of harm reduction 
programs in the country, where opiate drug users are encouraged to enter treatment 
programs (methadone treatment program). The shift from an enforcement approach to a 
public health approach may have contributed to the decline in drug related arrests in the 
country.    
1.3 Ketamine Use Histories in Malaysia  
Ketamine was first invented in 1962 by Calvin Stevens at the Parke-Davis 
laboratories in Michigan (Jansen, 2000). Ketamine effects were related to PCP 
(phencyclidine). It was reported to have shorter acting and less toxic effects and 
produces trance-like ‘dissociative anesthesia’ (Domino et al., 1965). Psychedelic drugs 
such as LSD, as well as psilocybin are emotionally exhausting and can elicit unpleasant 
effects when used frequently (Jansen and Cankovic, 2001). Some individuals claimed 
that it is easier to use ketamine, since it creates a state of unemotional “high 
indifference” (Lilly, 1978). With prolonged use, ketamine effects resemble aspects of 
cocaine, opium, cannabis and alcohol. Noteworthy, tolerance to ketamine can also 
develop rapidly, after one large dose of use (Meliska & Trevort, 1978). Ketamine has 
both direct and indirect effects on opioid receptors (Hirota et al., 1999). Despite giving 
rise to a rapid tolerance for itself, ketamine can block the development of tolerance and 
physical addiction to many other drugs, including heroin, alcohol and benzodiazepines 
(Khanna et al., 1998). In addition, ketamine can also suppress withdrawal symptoms in 
heroin addicts (Shimoyama, 1996).         
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In 1970, the Food and Drug Administration (FDA) approved ketamine for 
medical use in human. However, since 1980s ketamine popularity increased and 
ketamine was mainly used in dance culture, parties and raves among adolescents (Curran 
& Morgan, 2000). Pharmacologically, ketamine is an N-methyl-D-aspartate (NMDA) 
receptor antagonist. It is commonly used as a short-acting ‘dissociative anesthetic’ agent 
for medical purposes. Historically, ketamine gained notoriety during the Vietnam War 
where it was used by soldiers to suppress pain cause by physical trauma. Ketamine is a 
psychoactive drug and is commonly snorted (snapped) via the nostril to obtain a 
‘hallucinatory effect’. Ketamine is also popularly known as K among ketamine users for 
non-medical use. Ketamine users often report that ketamine could induce dissociative-
disorder commonly referred to as k-hole or out-of-body experience (Muetzelfeldt et al., 
2008).  
Ketamine act as a stimulant at lower doses (White & Ryan, 1996), and as a 
psychedelic drug because it can reveal aspects of how the mind constructs reality, 
personality, and a sense of meaning and sacredness, without necessarily inducing a toxic 
delirium (Jansen, 2000). Ketamine effects can be felt about 30 seconds after an 
intravenous injection, two to three minutes after an intramuscular injection, five to ten 
minutes after intranasal use, and 10 to 30 minutes after oral intake. Moreover, the use of 
ketamine has been linked with a wide range of mental health problems including 
anxiety, panic attacks, flashbacks, posttraumatic stress disorder, persistent perceptual 
changes, depression and unpleasant feeling of being unreal or that the world is unreal to 
ketamine users (Jansen, 2000). Nevertheless, ketamine could also induce cognitive 
impairments (Curran & Morgan, 2000). In addition, ketamine users may also 
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experienced difficulty with balance, numbness, muscle weakness and impaired vision, 
often resulting in lethal falls. In fact, K cramps are also known as severe abdominal 
pains commencing after high dose or daily ketamine use (Jansen & Cankovic, 2001).    
Since 2006, cases related to ketamine urological problems begun to emerge in 
recreational ketamine  users (Shahani et al., 2007; Tsai et al., 2009; Mak et al., 2011; Pal 
et al., 2013; Mason et al., 2010; Ng et al., 2013; Huang et al., 2008; Chu et al., 2008; 
Garcia-Larrosa et al., 2012; Winstock et al., 2012; Gray & Das, 2012; Chen et al., 2011; 
Middela & Pearce, 2011; Oxley et al., 2009). Among some of the commonly reported 
side-effects of ketamine use among recreational ketamine users include dysuria, urinal 
frequency, urgency, incontinence, nocturia and heamaturia (Shahani et al., 2007; Tsai et 
al., 2009; Chan et al., 2013; Chen et al., 2013). Approximately, 20-30% of ketamine 
abusers suffer from lower urinary tract symptoms (Muetzelfeldt et al., 2008; Chu et al., 
2008). Study conducted by Tsai et al, (2009) found ketamine users who used ketamine 
for about 1 to 4 years or for at least 1 month period have higher probability of 
experiencing lower urinary tract symptoms. Similarly, findings from Chao & Shai, 
(2010) also reported that ketamine users who use ketamine regularly for three years are 
more likely to develop depressive symptoms and lower urinary tract problems. While, a 
study conducted by Chen et al, (2011) also reported that those who use ketamine for 12 
months period have higher odds of developing urinary tract problems. As illicit ketamine 
become more available, it’s illegal use is anticipated to cause severe bladder problems 
(Tsai & Kuo, 2014). In fact, cessation from ketamine use has been reported to help 
reduce the deterioration of bladder symptoms in ketamine users (Winstock et al., 2012). 
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Figures from the Royal Malaysia Police 2014 showed, in 2009 and 2010 a total 
of 2,214 and 6,737 people were arrested for ketamine use. The number of people 
arrested for ketamine use has decreased significantly from 4,687 in 2011 to 1,092 in 
2014, as shown in Figure 1.6. The drop in the number of ketamine arrests could be 
attributed to the decrease in police raids conducted on entertainment outlets and also the 
hidden nature of these users who often use ketamine as recreational drug in 
entertainment settings. On the other hand, as shown in figure 1.5, the seizure for 
ketamine has been increasing since 2011.  
Figure 1.6 Ketamine users arrests from 2009 to 2014. 
 
 
                                       Source: Royal Malaysia Police 2014. 
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1.4 Problem Statement 
At this juncture, there are limited studies on ketamine use and its health impact in 
Malaysia. Ketamine a NMDA receptor antagonist is an anesthetic agent commonly used 
in hospital settings for its sedative and analgesic properties (Tsai & Kuo, 2014). From its 
traditional medicinal use, ketamine is now popularly used for its narcotic properties 
mainly among young club goers in entertainment settings. Ketamine is known as a club-
drug in Malaysia, as well as in China, Taiwan and Hong Kong. Ketamine begun to gain 
popularity in 1970s, and its widespread use was linked with club scenes and rave parties 
(Curran & Morgan, 2000). Recreational ketamine use is reported to cause adverse health 
problems such as lower urinary tract symptoms (LUTs) in regular ketamine users (Wood 
et al., 2011; Middela & Pearce, 2011; Chu et al., 2008; Tsai et al., 2009; Shahani et al., 
2007; Pal et al., 2013; Mak et al., 2011; Mason et al., 2010; Meng et al., 2013).  
Ketamine used was first reported in Malaysia in early 2001, where it was used 
recreationally in entertainment settings (Royal Malaysia Police, 2014). So far there are 3 
published studies on ketamine use in Malaysia (Lee et al., 2009; Ho et al., 2010; Robson 
et al., 2010). These three single case reports mainly describe the health problems 
associated with frequent ketamine use. To date, no studies have described the socio-
demographic characteristics and the contextual use of ketamine among ketamine users in 
Malaysia. The current data on ketamine arrests does not completely describe the socio-
demographic characteristics of ketamine users and the side-effects of ketamine use. 
Ketamine users are still seen as a ‘hidden population’ in Malaysia, since ketamine is 
commonly used in entertainment setting unlike on illicit drugs which are used on the 
streets. There is a need to understand this clandestine nature of ketamine use and the 
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socio-demographic characteristics of ketamine users in Malaysia. It is evident that illicit 
ketamine use can cause various health problems. Hence, conducting a study to 
understand the effects caused by ketamine use is important to treatment providers. This 
emerging health problem may also be under-reported as health care professionals 
dealing with drug users or ketamine users may not be trained to detect the symptoms and 
effects of ketamine use. As a result of this research paucity, this study aims to described 
the socio-demographic characteristics, contextual use and health problems associate with 
ketamine use in regular ketamine users in the states of Penang (Georgetown), Kuala 
Lumpur and Johor Bahru. It is hoped that the findings from this study can help provide 
the necessary information to guide healthcare professionals and policymakers designed 
proper prevention and treatment interventions for ketamine users in the country.  
1.5 Research Questions 
The research questions for the study are as follows;  
1. What are the socio-demographic characteristics of ketamine users in Malaysia? 
This question will elicit respondents’ demographic characteristics such as 
ethnicity, gender, age, marital, income and education status, as well as 
employment and incarceration history.  
2. What is the contextual use of ketamine in Malaysia? 
The second question will collect information related to respondents’ history of 
ketamine use, frequency and quantity of ketamine use, physical and 
psychological symptoms of ketamine use, reasons for ketamine initiation, risky 
sexual behaviours and history of poly-drug use.  
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3. To what extend do ketamine users develop ketamine induced health problems in 
Malaysia? 
The third question of the study will focus on common health problems reported 
by ketamine users.  
4. How does the duration of ketamine use affect ketamine induced health problems 
among users in Malaysia?  
The fourth question of the study will try to determine the association between 
duration of ketamine use with several health symptoms in ketamine users in this 
study.  
 
1.6 Study Objectives 
 
The study objectives are as follows;  
 
1. To described the socio-demographic characteristics of ketamine users in 
Malaysia. 
2. To described the contextual use of ketamine in Malaysia.   
3. To identify ketamine induced health problems among ketamine users in 
Malaysia. 
4. To assess the association between duration of ketamine use and ketamine 
induced health problems among users in Malaysia. 
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1.7 Scope of Study 
To have a better understanding on the socio-demographic characteristics, 
contextual use and health problems associated with ketamine use in Malaysia, a total of 
n=150 regular ketamine users were recruited for this cross-sectional study. The study 
was mainly conducted in three most economically advanced states (Penang, Kuala 
Lumpur and Johor Bahru) in the Malaysian Peninsular where most of the entertainment 
outlets are located. The study population mainly consists of ‘out-of-treatment’ regular 
ketamine users. The entire sample reported using ketamine recreationally in 
entertainment settings where ketamine is usually promoted as a club-drug.   
1.8 Significance of Study 
This study aims to determine the socio-demographic characteristics, contextual 
use of ketamine and ketamine health problems in ketamine users in Malaysia. At 
present, there are limited studies on ketamine use in Malaysia. In fact, the National Anti-
Drug Agency (NADA) does not collect any information on ketamine users in the 
country though using ketamine was an offence in Malaysia. The only data on ketamine 
use was on ketamine related arrests and seizures which are provided by the Royal 
Malaysia Police. Previous studies on ketamine use were merely based on single case-
reports and review article (Robson et al., 2010; Lee et al., 2009; Ho et al., 2010), which 
highlighted the adverse effects of ketamine consumption. It is hoped that the findings 
from this study will be able to describe the context of ketamine use and its associated 
health problems among a cohort of regular ketamine users who were recruited from an 
entertainment setting in Malaysia. Nevertheless, healthcare providers and policymakers 
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can also used the study findings to develop suitable evidence-based preventive and 
treatment interventions for illicit ketamine users in the country.  
1.9 Terminology 
Some of the common terminologies used in this text are elaborated below for the 
ease of understanding.  
Ketamine.  Ketamine is a NMDA receptor antagonist commonly used as 
an anesthetic agent for clinical use.  
Lower Urinary Tract 
Symptoms (LUTs). 
Unpleasant symptoms associated with urinary tract problems.  
Club-drugs. Illicit synthetic substances that are popularly used in 
entertainment settings. 
ATS.  Amphetamine-Type-Stimulants 
(methamphetamine/amphetamine) are psychostimulants, 
mainly use for its psychotropic effects. 
Frequent urination. Increase episodes of urination. 
Nocturia. An individual has to wake at night one or more times to 
urinate. 
Incontinence. Is also known as urinary incontinence where an individual 
experience the inability to hold its urine (leakage of urine).  
Urgency. Is also known as urinary urgency where an individual 
experience a sudden compelling urge to urinate.  
Interstitial cystitis. Is also known as bladder pain syndrome, where an individual 
experience chronic inflammatory condition of the submucosal 
and muscle layers of the bladder.  
Dysuria. Is also known as painful urination (burning or stinging 
sensation felt during urination).  
Erectile-dysfunction. Is also clinically known as impotence. It’s a sexual 
dysfunction characterized by the inability to develop or 
maintain an erection of the penis during sexual activity in 
humans.  
Poly-drug users. Individuals who use more than one illicit drug or a 
combination of several different classes of illicit drugs.  
Menstrual cycle. Is also known as irregular menstruation cycle. Is a regular 
natural change that occurs in the female reproductive system, 
specifically the uterus and ovaries.  
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1.10 Study Limitation 
This study has few limitations and has been clearly highlighted. Respondents 
were non-randomly recruited using snowball-sampling technique for this study, thus it is 
impossible to generalize the findings of the study because it does not represent the whole 
ketamine using population in the country. Respondents responses were based on their 
self-report, thus it is bound to social and recall biasness. Some of the reported health 
problems in this study may emerge or caused by other underlying medical conditions 
and not necessarily from ketamine use alone. Due to this limitation, it is certainly 
difficult to fairly conclude that ketamine use is harmful. Inevitably, there was also 
inconsistency in respondents self-reports, because few of the Chinese respondents were 
not able to clearly understand the research questions that were constructed in the Malay 
language. Ideally, a Chinese translated set of questionnaire could have been use among 
few Chinese respondents who have difficulty comprehending the questions in Malay. 
This could help increase the reliability of their self-report. Finally, there could be a 
discrepancy in respondents self-reports and the context of ketamine use, since the study 
was largely conducted among a group of ketamine users who regularly frequented 
entertainment outlets. Future studies must strive to recruit a more representative sample 
of ketamine users from varied settings.  
1.11 Conclusion 
This chapter provides the background to the world drug problem, the substance 
abuse scenario in Malaysia, pharmacological effects of ketamine, problem statement of 
study, study objectives and research questions, as well as the scope and limitations of the 
study. The next chapter describes the literature review. The global and local substance 
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abuse problem, drug treatment policy in Malaysia, problems associated with HIV 
infections, recent and previous publications on ketamine use in human, and the 
fundamental components of addiction (e.g. dependence, withdrawal, tolerance) are 
discussed in the second chapter of this thesis. There are six chapters altogether in this 
thesis and the summary of each chapter is shown below. 
Chapter 1: In the first chapter, the global scenario on drug use, scenario on drug use in 
Asia and Malaysia, classification of party drugs for this study, research questions, study 
objectives, and study limitations are clearly elucidated. 
Chapter 2: The second chapter covers the literature review. In this chapter, all the 
relevant and important literature relating to the study is delineated. 
Chapter 3: The third chapter is the methodology chapter. In this chapter, all the 
methods undertaken in this study are discussed. 
 Chapter 4: The fourth chapter is the results chapter. All the results are described and 
presented in this chapter. 
Chapter 5: The fifth chapter is the discussion chapter where the findings of this study 
are discussed with other previous studies. 
Chapter 6: The sixth chapter is the final chapter of the thesis. In this chapter all the 
findings are summarized. The implication of this study is also discussed. It also provides 
some recommendations on how to improve and conduct future studies related to 
ketamine use in Malaysia. This final chapter also addresses some of the current gaps in 
the existing studies on ketamine use in Malaysia. 
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CHAPTER   2 
LITERATURE REVIEW 
2.0 Introduction 
In the second chapter of this thesis all relevant literatures on ketamine are 
discussed. The chapter starts by providing a background to the definition of drugs, 
followed by world and Malaysia drug abuse problems, drug policy in Malaysia, 
health consequences related to drug use, drug addiction theories, drug laws in the 
country and specifically all relevant literature related to ketamine are discussed in 
this chapter.      
2.1 Drugs 
Psychoactive drugs or narcotics are chemical compounds that can influence 
our subjective perceptions and behaviour (Muller and Homberg, 2015). Addiction, 
originates from a Latin word ‘addicere’ (which means to sentence) is a chronic 
relapsing brain disorder (Milton and Everitt, 2012). In fact, drug addiction can be a 
chronic problem (McLellan et al., 2000; Hser et al., 2001). Drug users usually take 
drugs because psychotropic substances can produce potent effects on primary and 
secondary reinforcement mechanisms. Based on the incentive sensitisation theory of 
addiction (Robinson and Berridge, 1993) there may be dissociations in the neural 
systems underlying reward and reinforcement. A drug outcome could act as a strong 
reinforcer by activating the wanting system, without having any effect on the liking 
system and could probably elicit hedonic responses (Milton and Everitt, 2012).      
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The term illicit drugs are drugs under International Control, which have been 
produced, trafficked and consumed illegally (UNODC, 2015). Substance abuse refers 
to the harmful use of psychoactive substances, including alcohol and illicit drugs 
such as opiates, cannabis and amphetamine-type-stimulants (ATS). In fact, the abuse 
of narcotic substances can lead to dependence syndrome, a cluster of behavioural, 
cognitive and physiological manifestations that develop after repeated substance use, 
where drug users often experienced a strong desire to use drugs, difficulties in 
controlling its use, continuous use despite harmful consequences, more importance 
given to drug use activities, increased tolerance and a withdrawal state 
(www.who.com).   
2.2 Overview of Global Illicit Drug Use 
In 2012 United Nations Office on Drugs and Crime (UNODC) estimated that 
there are around 162 and 324 million people (3.5% to 7% of the population) aged 
between 15 to 64 years who have used illicit substances. While the extent of problem 
drug use, range from 16 to 39 million people (equivalent to 0.3% to 0.9% of the 
population) aged 15-64 (UNODC, 2014). Table 2.1 shows the global categorisation 
of illicit drug use. Cannabis remains the most widely used illicit substance and the 
estimated number of cannabis users were around 125 and 227 million in 2012, 
equivalent to a prevalence rate of 2.7%-4.9% of the population aged 15-64 years old 
(UNODC, 2014). While, the second most widely used group of substances is ATS 
(including methamphetamine, amphetamine and ecstasy). There are between 24 and 
84 million ATS users or equivalent to a prevalence rate ranging from 0.5%-1.8% of 
the population aged 15-64 in 2012. The broad ranges in the number of ATS users are 
mainly due to the uncertainties in ATS users in China, India and Africa (UNODC, 
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2014:pp.2). Nevertheless, Opiates remains the third most widely used group of 
substances with estimates ranging from 42 to 58 million people, equivalent to a 
prevalence rate of 0.9%-1.2% of the population aged 15-64 in 2012. In recent years, 
problem drug use has also been related to the non-medical use of various prescription 
Opioids. Cocaine appears to rank fourth in terms of global prevalence, with an 
estimated of 14 to 21 million people, equivalent to a prevalence rate that ranges from 
0.3%-0.5% of the population aged 15-64 in 2012 (UNODC, 2014:pp.2). 
         Table 2.1 Global estimates of users of different drugs in 2012 (aged 15-64) 
 
                        
        
                                
                                                               
 
 
 
 
                                                            Source: UNODC, 2014:pp.2. 
 
The emergence of New Psychoactive Substances (NPSs) in the current drug 
market is not a new development. Recently, seizures of new psychoactive substances 
(NPS) have been expanding rapidly. NPSs are now commonly found and used in 
Europe and North America, Oceania, Asia, South America, and few African 
countries. Only 166 NPSs were reported between 1997 and 2009. Surprisingly, a 
total of 348 NPSs were identified in 2013. In fact, the prevalence of ketamine use fell 
from 2.1% to 0.8% in 2012 (UNODC, 2014).  
 
 
 
 
 Number of users (millions) Prevalence (percentage) 
 Low High Low High 
Cannabis 125.30 227.27 2.7 4.9 
Opiates 41.43 58.39 0.88 1.23 
Cocaine 13.99 20.92 0.3 0.45 
ATS 13.94 54.81 0.3 1.2 
Ecstasy 9.4 28.24 0.2 0.6 
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2.3 Overview on Asia’s Illicit Drug Use and Production 
 Opium is widely produced and used in Asia. Based on World Drug Report 
2014 the two largest opium-producing countries are Afghanistan and Myanmar. In 
Afghanistan the opium cultivation area have increased by 36% in 2013. In fact, total 
opium production in Afghanistan accounts for 80% of the global opium production 
in 2013 (UNODC, 2014). Cannabis production remains widespread in most regions, 
where almost every country in the world produces it through personal cultivation or 
large-scale farming (UNODC, 2014). In addition, Asia has developed into a major 
production and trafficking hub for amphetamine-type-stimulants (ATS), accounting 
for 64% of worldwide ATS seizures in 2009 (UNODC, 2011:pp.42). A total of 144 
tons of ATS was seized in 2012; approximately half were seized in North America 
and a quarter in East and South-East Asia (UNODC, 2014:pp.46). There are 
indications that large quantities of ATS are being manufactured chiefly in East and 
South-East Asia. Between 2008 and 2011, dismantle clandestine ATS labs increased 
from 300 in 2009 to 560 in 2011. Moreover, an increasing number of clandestine 
ATS laboratories have been discovered in New Zealand, Australia, Cambodia, Hong-
Kong, China, India, Indonesia, Japan, North Korea, Malaysia, Myanmar, Philippines 
and Sri Lanka (Global Synthetic Drugs Assessment, 2014). In July 2006, Malaysian 
enforcement authorities busted the world’s largest clandestine methamphetamine 
manufacturing laboratory in Malaysia (Kozel et al., 2006).  
Ketamine is popularly used in most Asian countries, notably in East Asia. 
Figures from the Global Synthetic Drugs Assessment (2014) showed in 2012 
ketamine was the second most used drug in Macau and China. Total ketamine 
seizures in China and Hong-Kong have accounted for almost 60% of global ketamine 
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seizures between 2008 and 2011. Relatively high levels of ketamine use have also 
been reported in Southern Asian regions like India, Myanmar, Brunei Darussalam, 
Japan, Singapore, Indonesia and Malaysia (Global Synthetic Drugs Assessment, 
2014). In 2012, a total of 81 ketamine laboratories were discovered in China. Most of 
the world-wide ketamine seizures originate from China, India, Cambodia and 
Taiwan. Around 2.2 tons of ketamine have been seized in Malaysia from 2009 and 
2011(Global Synthetic Drugs Assessment, 2014:pp.30). In 2012, ketamine has also 
been found in tablet form, and sold as methamphetamine in some countries, such as 
in Indonesia and Australia (Global Synthetic Drugs Assessment, 2014). In Asia, 
cannabis is the most commonly used illicit substance, with an annual prevalence use 
of 1.9% among those aged 15-64 years, followed by ATS at 1.1%, opiates at 0.35% 
and cocaine at 0.05% (UNODC, 2014). Notably, the use of methamphetamine 
continues to rise in East and South-East Asia countries, with accompanying seizures 
of methamphetamine in pills and crystalline forms.   
2.4 Types of Illicit Drugs Used and Total Drug Users in Malaysia 
Malaysia first began to experience with drug abuse problem during the 
British invasion in Malaya. During the British colonisation in Malaya, Chinese and 
Indian manual labourers were brought in by the British to work in tin mines, rubber 
plantations and pepper estates. The Chinese workers were the first people who 
introduced opium smoking, while the Indian workers particularly the dockworkers 
used cannabis. By 1929, the Federated Malay States had 52,313 registered opium 
users and in 1941, there were approximately 75,000 opium users in Malaya (Rani, 
2007). The combination of ‘hippy culture’ and the consequences of the Vietnam War 
in the late 1960s saw a shift in the pattern of drug usage in Malaysia. Hence, drug 
